Biotech Show Case: looking for partners to pursue the development of our Nanocyclix® technology products together!

Biotech Show Case: the place to be for licensing innovation

Through its Nanocyclix® technology, Oncodesign identifies small macrocyclic molecules capable of inhibiting with high potency and selectivity both known and unexplored kinases.

A wide variety of kinase inhibitors are continuously explored and the most promising inhibitor/kinase combinations are selected for further evaluation.

Oncodesign has built up a portfolio of projects with promising potential to treat serious diseases with no known treatment.

This portfolio contains both molecules already in advanced clinical development and molecules at an earlier stage of development.

Please contact Dr. Jan Hoflack – Chief Scientific Officer and Executive Director, Head of the Biotech BU – to discuss Oncodesign’s partnership and licensing opportunities:

A pre-IND stage RIPK2 inhibitor with potential in multiple autoimmune and inflammatory indications is presented for partnership/licensing

– Programs in the optimization phase are available for partnership on attractive kinases: MNK1/2, ALK2,  PIKFYVE, CDK7, PI3Kg, RET, FAK, ACK

– Partnerships based on Nanocyclix® according to your kinase targets

We will be attending upcoming Biotech ShowCase in person to find value partners for licensing. The place to be to meet innovation’s actors.

I schedule an appointment with Jan Hoflack | Biotech BU

Share: